Theravance Biopharma Stock Forecast, Price & News

-0.18 (-1.37 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume320,560 shs
Average Volume274,929 shs
Market Capitalization$847.33 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Theravance Biopharma logo

About Theravance Biopharma

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.04 out of 5 stars

Medical Sector

253rd out of 842 stocks

Pharmaceutical Preparations Industry

112th out of 324 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

Is Theravance Biopharma a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Theravance Biopharma stock.
View analyst ratings for Theravance Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Theravance Biopharma?

Wall Street analysts have given Theravance Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Theravance Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Theravance Biopharma

How can I listen to Theravance Biopharma's earnings call?

Theravance Biopharma will be holding an earnings conference call on Tuesday, August 3rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "2615108".

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, May, 3rd. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $0.19. The biopharmaceutical company had revenue of $14.26 million for the quarter, compared to the consensus estimate of $17.50 million.
View Theravance Biopharma's earnings history

How has Theravance Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TBPH stock has decreased by 47.7% and is now trading at $12.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TBPH?

6 Wall Street analysts have issued 12 month target prices for Theravance Biopharma's shares. Their forecasts range from $27.00 to $36.00. On average, they anticipate Theravance Biopharma's share price to reach $31.00 in the next year. This suggests a possible upside of 138.8% from the stock's current price.
View analysts' price targets for Theravance Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Mr. Rick E. Winningham M.B.A., Chairman & CEO (Age 61, Pay $1.6M)
  • Mr. Andrew Asa Hindman, Sr. VP & CFO (Age 48, Pay $822.81k)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations (Age 49, Pay $1.17M)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 61, Pay $827.37k)
  • Ms. Gail B. Cohen, VP of Corp. Communications & Investor Relations
  • Mr. Dennis O. Driver, Sr. VP of HR, Organizational and Leadership Devel.
  • Mr. Frank Pasqualone, Sr. VP & Chief Bus. Officer (Age 65)
  • Dr. Phillip D. Worboys, Sr. VP of Research & Translational Science (Age 51)
  • Dr. Kenneth R. Pitzer, Sr. VP of Product Strategy & Commercial Planning (Age 57)
  • Mr. Daniel Long, Head of Medicinal Chemistry

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Theravance Biopharma stock include Brett K Haumann, Philip D Worboys, Richard A Graham and Vijay Sabesan.
View institutional ownership trends for Theravance Biopharma

Which institutional investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Theravance Biopharma company stock in the last year include Brett K Haumann, Philip D Worboys, and Richard A Graham.
View insider buying and selling activity for Theravance Biopharma
or view top insider-selling stocks.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $12.98.

How much money does Theravance Biopharma make?

Theravance Biopharma has a market capitalization of $847.33 million and generates $71.86 million in revenue each year. The biopharmaceutical company earns $-278,020,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

How many employees does Theravance Biopharma have?

Theravance Biopharma employs 359 workers across the globe.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is

Where are Theravance Biopharma's headquarters?

Theravance Biopharma is headquartered at UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.